secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0001213900-25-051750
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics raises ~$750k in Series D financing; first-in-human dosing under way
--------------------------------------------------------------------------------

- Gross proceeds from additional closing ~$750k; total Series D up to $8M with $5M previously issued.
- Series D convertible preferred converts to common; additional $2.25M possible at investors' option.
- Proceeds to support clinical development of CAR-T candidate CER-1236, including IND allowances and site activation at MDACC.
- Company reports first-in-human dosing in AML for CER-1236, a TIM-4L-targeted autologous CAR-T.
- CEO Chris Ehrlich cites continued investor support and clinical progress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025051750/0001213900-25-051750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025051750/ea0244845-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-051750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer